Cognition Therapeutics Q2 Loss Narrows to $3.9M, Cash Runway Extended to Q4 2027
CGTX has more than doubled off its 52-week low of $0.55.
Summary
Cognition Therapeutics reported a Q2 net loss of $3.93 million, a sharp improvement driven by lower R&D spending as trial activities wound down. The company ended the quarter with $34.8 million in cash and now expects its runway to extend into Q4 2027, a notable extension from the prior Q2 2027 guidance. This follows the recent FDA alignment on the pivotal Phase 3 trial design for zervimesine in DLB psychosis, and a new patent allowance could protect the asset through 2045. The improved cash position reduces near-term dilution risk as the company advances toward the registrational program.
At the time of this announcement, CGTX was trading at $1.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $101.1M. The 52-week trading range was $0.55 to $3.83. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.